EV/EBITDA Multiple: Akero Therapeutics Inc (AKRO)

Corporate company logo of akerotx.com (AKRO)

The reliability of Akero Therapeutics (AKRO) is based on the diversification of its laboratories, which guarantees supply chain stability. The company's EV/EBITDA ratio on the GURU.Markets chart confirms this, with the current level standing at 0.00. Success is driven by elite scientists with lucrative options, while the active recruitment of experts for clinical trials facilitates the efficient scaling of current biopharmaceutical projects.

AKRO (Akero Therapeutics, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 12/20/2025

Akero Therapeutics, Inc. (AKRO) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart akerotx.com|AKRO - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Akero Corp|AKRO - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Akero Therapeutics|AKRO - Total Net Assets|Market Capitalization to Book Value Ratio akerotx.com|AKRO - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Akero Therapeutics|AKRO - Long-Term Debt to Equity|Short-Term Debt to Equity akerotx.com|AKRO - Company Cumulative Debt|Debt to Book Capitalization Ratio Akero|AKRO - Company Long-Term Debt|Company Short-Term Debts Akero Therapeutics|Quick Liquidity akerotx.com
- net income and valuation multiples indicators:
AKRO - Net Financial Result|Expected Profit Akero Therapeutics|AKRO - Price to Earnings Ratio|Forward P/E Multiple akerotx.com|AKRO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akero Therapeutics|AKRO - Operating profit EBITDA|Net earnings per share (EPS TTM) Akero Therapeutics|AKRO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months akerotx.com|AKRO - Earnings per share increase in current year|Net earnings per share growth forecast for next year Akero Therapeutics
- issuer revenue and sales details:
AKRO - Company Total Revenue|Company Future Sales Volume Akero Therapeutics|AKRO - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Akero Corp
Initial company analysis:AKRO (Akero Therapeutics)
Product sample of Akero

This metric compares the total enterprise value, including debt, with operating profit before depreciation and amortization, allowing for an assessment of the real value of assets regardless of the tax burden. By analyzing the EV/EBITDA multiple trend, an investor can track the development efficiency of the NASH drug at Akero Therapeutics (AKRO), assessing the company's market value relative to its current operational potential, excluding merger scenarios.

Who Akero Therapeutics competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|MTSR (Metsera) - Enterprise Value to EBITDA Ratio|MLTX: Enterprise Value to Operating Income Before Depreciation Ratio|CRNX (Crinetics Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (Amicus Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio.com ETNB|Agios Corp (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Corp|Enterprise Value to EBITDA Ratio Altimmune Corp (ALT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aardvarktherapeutics.com (AARD)|Enterprise Value to EBITDA Ratio sagimet.com SGMT|EV/EBITDA Multiple BIOA (BioAge)|Biomea Fusion - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation